To Get Full Access :

Vizz

Vizz is the first and only aceclidine-based eye drop approved for adults with presbyopia. Presbyopia is an age-related blurry near vision. By selectively contracting the iris sphincter muscle to create a pinhole effect and achieve a sub-2 mm pupil—without significant ciliary muscle stimulation—it extends depth of focus to provide fast, steroid-free relief of near-vision blur that lasts up to 10 hours. It offers a safe, once-daily, non-surgical alternative to traditional reading glasses and contact lenses.

Molecule Details :

  • Molecule Name :

    Aceclidine
  • Innovator :

    LENZ THERAPEUTICS INC
  • Approval Date :

    31-Jul-25
  • NCE-1 Date :

    31-Jul-29
  • NCE Date :

    31-Jul-30
  • Dosage Form :

    Ophthalmic Solution/Drops
  • Strength :

    EQ 1.44% BASE
  • Therapeutic Category :

    Antiglaucoma Agents
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    4
  • 2026 :

    56
  • 2027 :

    148
  • 2028 :

    213
  • 2029 :

    284
  • 2030 :

    357
  • 2031 :

    428
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?